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Stlmmary 
We have previously demonstrated that bacterial lipopolysaccharide (LPS) is capable of promoting 
Coxsackie B3 (CB3)-induced myocarditis in genetically resistant B10.A mice. Because LPS is 
known to increase production of various cytokines, we tested CB3-infected, LPS-treated mice 
for the presence of interleukin 1 (II.-1) and tumor necrosis factor (TNF). We found significantly 
increased amounts of both cytokines in the sera of CB3/LPS-treated mice compared with animals 
treated only with LPS.  We also found immunohistochemical evidence for local production of 
these cytokines in the cardiac tissue of CB3/LPS-treated mice. Treatment with IL-1 or TNF 
alone promoted CB3-induced autoimmune myocarditis in resistant B10.A mice. Myocarditis was 
also observed when uninfected mice were immunized with syngeneic heart extract in the presence 
of 1I.-1 or TNF. 
I 
nfection of mice with Coxsackie virus B31 (CB3) results 
in myocyte necrosis and an inflammatory response within 
the myocardium consisting of focal infiltrates of polymor- 
phonuclear cells, lymphocytes, and macrophages. The early 
pathological manifestations of viral injury gradually diminish 
so that by 14 d after infection, the acute phase of myocarditis 
is resolved. In some genetically predisposed mouse strains such 
as A/J (H-2~), this acute phase is followed by a chronic, au- 
toimmune myocarditis characterized by diffuse interstitial 
mononuclear cell infiltrates and by the presence of heart-spedfic 
autoantibodies  (1). C57BL/10 H-2 congenic mice (e.g., B10.A, 
H-2')  are not susceptible to the chronic, autoimmune dis- 
ease, and recover spontaneously from the initial myocarditis. 
We have recently reported that LPS  treatment of CB3- 
infected B10.A mice is capable of inducing autoimmune myo- 
carditis in these genetically resistant animals (2). Because LPS 
is  capable  of stimulating  increased production of various 
cytokines (3), it is possible that these immunomodulators, 
along with the CB3 viral infection of B10.A mice, contribute 
to the development of autoimmune myocarditis. To inves- 
tigate this possibility we examined the sera and hearts from 
CB3-infected, LPS-treated B10.A mice for the presence of 
I1.-1 and TNF, which are the major cytokines produced by 
macrophages  when  treated  with  LPS  (4,  5).  We  found 
1 Abbreviations used in this paper: CB3, Coxsackie  B3; HE, heart extract; 
TBS, Tris buffered  saline. 
significantly increased amounts of both cytokines in the sera 
of CB3/LPS-treated mice when compared with animals treated 
only with LPS,  or infected only with CB3,  and immuno- 
histochemical evidence for  the local  production  of these 
cytokines in the cardiac tissue of CB3/LPS-treated mice. We 
also report the ability of treatment with II.-1 or TNF alone 
to promote CB3-induced autoimmune myocarditis in resis- 
tant B10.A mice. Additionally, when uninfected mice were 
cotreated with II.-1 or TNF, and immunized with syngeneic 
heart extract as a source of myosin, myocarditis was observed, 
but was absent in the mice injected only with the heart pro- 
teins. This finding indicates an ability of these immunomodu- 
lators to enhance immune reactivity against self-antigens. 
Materials  and Methods 
Animals.  The C57BL/10  (B10.A) mice were originally pur- 
chased from The Jackson Laboratory (Bar Harbor, ME), and bred 
and maintained in our animal facilities. 
Virus Preparation.  Preparation and titration  of CB3  (Nancy 
strain) using Vero monkey kidney cells has been previously de- 
scribed (6). 
Preparation of Syngeneic Heart Extract.  Hearts from untreated 
B10.A mice, 6-10 wk of age, were perfused with Tris buffered sa- 
line (TBS), pH 7.6, cut into small pieces, and then homogenized 
in TBS. Heart protein concentration was determined by the BCA 
protein assay  (Pierce  Chemical Co., Rockford, IL). Previous studies 
in our laboratory showed that myosin is the predominant autoan- 
tigen in heart extract (Foca et al., unpublished results). 
Treatment Protocol.  B10.A mice, 14-20 d of age, were inocu- 
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and IL-1 (CB3/Ibl), CB3 and TNF (CB3/TNF), CB3, LPS, IL-1,  12o 
TNF, or saline (100/~1). The CB3/LPS group was inoculated on 
day 0 with a  1:3 dilution  of 10  s TCIDs0 CB3 in 0.1  ml RPMI  loo 
1640, and with 25 #g LPS (from Salmonella minnesota Re 595; Sigma  p  so 
Chemical Co., St. Louis, MO) in 0.1 ml sterile saline. The CB3/IL-1  /g 
and CB3/TNF groups were similarly infected with virus, and treated  T  60 
with 100 ng of Ibl synthetic peptide fragment 163-171  (Sigma 
40 
Chemical Co.), and 250 ng TNF synthetic peptide fragment 114-130 
(ICN Biochemicals, Costa Mesa, CA), respectively. Dosages of LPS,  2o 
IL-1, and TNF  were experimentally determined as the amounts 
necessary to induce the greatest amount of histological and sero-  0 
logical evidence of myocarditis without causing >50% mortality 
in the mice. The CB3 group only received CB3 on day 0, the LPS, 
IL-1, and TNF groups received  treatment diluted in sterile  saline 
(no CB3). On day 4, the CB3/LPS and the LPS groups were treated 
again with LPS; the CB3/IL-1, and IL-1 groups were treated again 
with IL-1; the CB3/TNF and TNF groups of mice were treated 
again with TNF; and the CB3 and saline groups were treated with 
sterile saline (100 #1). Immunization of B10.A mice of similar ages 
was performed by subcutaneous injection into the inguinal region 
with  100 #g of B10.A  heart extract (HE) emulsified in IFA on 
days 0 and 7, or cotreated with HE and individual immunomodu- 
lators. The immunomodulators were prepared and injected as above 
on days 0 and 4. 
Histology.  2 wk after treatment, the mice were exsanguinated, 
perfused with heparinized saline, and the hearts removed. The hearts 
were cut  sagitally.  Half of each heart  was frozen for immuno- 
histochemistry, and the other half fixed in 10% buffered formalin 
for hematoxylin and eosin (H & E)  staining. 
Immunohistochemistry.  The indirect immunohistochemistry pro- 
cedure has been previously described (2) and was used to detect 
ILl- and TNF-secreting cells in the heart tissue.  IL-l-and TNF- 
secreting cells were identified by using a rabbit anti-routine IL-1 
reagent (Genzyme Corp., Boston, MA), and rabbit anti-TNF (En- 
dogen,  Inc., Boston,  MA),  respectively. 
ELISA for II~I and TNF Serum Levels.  Goat anti-murine ILl 
(R & D Systems, Inc., Minneapolis, MN) or rat anti-murine TNF 
(Endogen, Inc.) (100 #1 of 5 #g/ml solutions in PBS, pH 7.4) was 
added to the wells of ELISA plates (Costar Corp., Boston, MA), 
and incubated for 16-24 h at 4~  The plates were washed with 
PBS containing 0.05%  Tween-20 (PBS-Tween),  and 200/zl/well 
of a solution of PBS containing 4% BSA was added and incubated 
for 1 h at 370C. Serum samples were assayed neat and diluted 1:2 
and 1:4 in PBS-1% BSA. Murine rib1 (R & D Systems) or murine 
rTNF (Endogen, Inc.) was diluted in PBS-Tween, 1% BSA (1,000, 
500,  100, 50, 25,  10, and 1 pg/ml). The plates were washed with 
PBS-Tween and 100 #1 of rabbit anti-Ibl (K & D Systems) or rabbit  loo 
anti-TNF (Endogen,  Inc.) were added to the wells of the appro- 
priate assay plate and incubated for 2 h at 37~  The plates were  8o 
washed with PBS-Tween and 100/~1 of peroxidase-conjugated goat 
p  60  anti-rabbit IgG (Jackson Immunoresearch Laboratories, West Grove,  o 
PA) were added to the wells,  and the plates incubated for 2 h at 
37~  The plates were washed with PBS-Tween and 150/~1 of ABTS  T  4o 
substrate solution (Kirkegaard and Perry Laboratories; Gaithersburg, 
MD) were added to the wells for color development. A standard  20 
curve was obtained by plotting the resulting absorbance of the cyto- 
kine dilutions versus their concentrations. Cytokine concentration 
of the serum samples was determined by linear regression analysis. 
Results  and Discussion 
We have previously demonstrated  that LPS is capable of 
promoting CB3-induced autoimmune myocarditis in genet- 
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Treatment Group 
Serum was tested by ELISA for the presence of IL-1 in day  Figure 1. 
14 B10.A mice treated with CB3/LPS (n =  15), CB3 (n  =  15), or saline 
(n  =  10). No II:1 was detected in the serum of the saline-treated mice. 
ically resistant B10.A mice that is characterized by mononuclear 
cell infiltration  of heart tissue,  and by the presence of IgG 
autoantibodies  to heart  antigens  (2).  Gudvangen  et al.  (7) 
reported  that  treatment  of  CB3-infected,  myocarditis- 
susceptible  mice with  another  immunomodulator,  levami- 
sole, exacerbates the myocarditis that is observed compared 
with mice infected  only with  the virus.  We have observed 
that levamisole treatment of CB3-infected B10.A mice, like 
LPS, induces an autoimmune myocarditis in these resistant 
animals (unpublished observations). Reports that LPS induces 
macrophage secretion of ILl and TNF (3-5), and that levami- 
sole can enhance macrophage secretion of IL-1 (8), led us to 
examine what  role these cytokines may have in our model 
of autoimmune  myocarditis. 
In this  report,  serum  samples obtained  14  d  after treat- 
ment were tested for concentrations of IL-1 (Fig. 1) and TNF 
(Fig. 2). ILl and TNF were detected in the sera of mice treated 
with CB3/LPS  and LPS, but were not detected in mice in- 
fected with CB3  alone.  Mice that were treated with  saline 
did  not  have any detectable  serum  IL-1  or TNF  (data  not 
shown). Comparison of CB3/LPS- and LPS-treated mice re- 
vealed that both IL-1 and TNF serum levels were significantly 
greater in the CB3/LPS  group (121.2  +  10.6 pg/ml vs. 56 
Figure 2. 
r  T 
CB3/LPS  LPS  CB3 
Treatment Group 
Serum was tested by ELISA for the presence of TNF in day 
14 B10.A mice treated as in Fig. 2. No serum TNF was detected in the 
saline-treated mice. 
CB3-induced Myocarditis in Resistant BIO.A Mice _+  13.2 pg/ml, p <  0.001 for IL-1, and 88.1  _+  8.0 pg/ml 
vs.  40.4  _  6.2 pg/ml, p <  0.001 for TNF).  The elevated 
serum levels of IL-1 and TNF observed for the LPS-treated 
mice were to be expected, based on the actions of this im- 
munomodulator.  Although both  the CB3/LPS  and LPS 
groups of  mice were treated with equivalent amounts of  LPS, 
the CB3/LPS group had significantly higher serum levels of 
the cytokines, which was evident 9 d after treatment (data 
not shown), than did mice treated only with LPS. The on- 
going autoimmune process in the hearts of the CB3/LPS- 
treated mice may be attributed to this enhanced level of  both 
cytokines. Increased levels of ILl and TNF have been ob- 
served  in numerous chronic inflammatory conditions including 
autoimmune diseases. (9, 10). 
The pathogenic relevance of the circulating  serum levels 
of ID1 and TNF was demonstrated by the observation  of 
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Figure 3.  Inflammatory  cells in sequential sec- 
tions of heart tissue of CB3/LPS-treated mice con- 
sisted of monocytes and CD3 § cells. These cells 
stained positive using the antibodies specific for 
IL-1 (A) and TNF (B). Note in areas away from 
the major focus of  inflammatory cells (arrows),  both 
II.,1- and TNF-staining  cells were observed x420. inflammatory cells within the heart tissue appearing to se- 
crete these cytokines locally. Heart tissue samples obtained 
from the CB3/LPS-treated  mice 14 d after treatment were 
examined by immunohistochemistry  for the presence of 11:l- 
and TNF-containing cells among the heart inflammatory cells. 
Within an inflammatory lesion, both I1:1- (Fig. 3 A) and 
TNF- (Fig. 3 B) staining cells were observed. No cytokine 
staining cells were detected in the heart tissue of  control mice 
infected only with CB3 or treated only with LPS. Similar 
observations have been made in multiple sclerosis patients 
who have increased levels of TNF in the serum and spinal 
fluid (11), and who also have brain lesions containing TNF- 
secreting mononuclear inflammatory  cells (12). In our mice, 
it is likely that, upon treatment with LPS, macrophages and 
monocytes are activated and secrete cytokines to cause the 
systemic increase of I1:1 and TNF that is observed in the 
serum. CB3 infection of  heart tissue  promotes the local produc- 
tion of these cytokines by activated monocytes within the 
heart as a response to viral infection. In B10.A mice not treated 
with LPS, these monocytes may cooperate with other lym- 
1126  CB3-induced  Myocarditis  in Resistant  B10.A Mice Figure 4.  H&E sections of heart tissues of B10.A 
mice infected with CB3 (A) demonstrated  normal 
appearing hearts, and mice treated with CB3/IL-I 
(B) or CB3/TNF (C) were characterized by an ex- 
tensive mononuclear cell inflammation  x420. 
phoid cells to remove virus for a resolution of the acute phase 
of myocarditis. In contrast, the highly activated monocytes 
in LPS-treated mice may result in the persistence of these cells 
within the heart tissue,  even after virus is eliminated, and 
lead to  the development of chronic myocarditis. 
Supporting evidence for the involvement of Ibl and TNF 
in promoting myocarditis was observed when CB3-infected 
B10.A mice were treated with Ibl or TNF rather than LPS. 
Because LPS  has  many physiologic effects, in  addition  to 
cytokine production (13), peptide fragments oflbl and TNF 
were used. These peptides have been reported to have both 
in vitro and in vivo immunostimulatory activity (14-17),  and 
with our mice similar results were obtained whether we used 
the peptide fragments or the whole IL-1 or TNF molecule 
(data not  shown).  14 d  after treatment,  hearts from mice 
treated only with CB3  (Fig.  4 A),  Ibl,  or TNF  appeared 
normal, while hearts from mice given combined CB3/Ibl 
(Fig.  4 B) and CB3/TNF (Fig.  4 C) treatment were charac- 
terized by extensive mononuclear cell infiltration. These Ibl 
and TNF peptides promoted disease similar to that seen with 
LPS, even though they represent the minimal structure neces- 
sary to be immunostimulatory without inducing LPS-like 
pyrogenic and inflammatory effects. 
Our studies are the first to report the ability of cytokine 
treatment to convert a myocarditis-resistant strain of mice 
to become susceptible to myocarditis. There have been reports 
of cytokine modulation of other animal models of autoim- 
mune disease.  The  effects of Ibl  on  the development of 
collagen-induced arthritis  was  to  accelerate the onset  and 
progression of disease  (18),  and in the Biobreeding rat,  in 
vivo treatment with IL-1 was found to modulate idiopathic 
autoimmune diabetes and thyroid disease in a dose-dependent 
manner (19). 
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It is interesting to note that treating infected mice with 
either IL-1 or TNF promoted similar disease.  Regardless of 
which treatment the mice received, the other cytokine was 
detected in the serum and present within the cytokine-secreting 
cell population at equivalent levels (data not shown). This 
is most likely due to the ability of each cytokine to induce 
the production of the other (9, 20) and to act synergistically 
(21).  Ongoing studies in our laboratory using anticytokine 
treatment are examining whether such synergy is operating 
in this model, or whether one of the cytokines is produced 
as a byproduct of the inflammatory process (10). We also are 
performing time course studies of these mice to identify the 
heart inflammatory cells,  and to determine the local heart 
inflammatory cell productionAerum levels of Ibl and TNF 
(our manuscript in preparation). Preliminary evidence indi- 
cates that, regardless of  whether infected mice are treated with 
LPS, Ibl, or TNF, an initial, limited, monocyte inflamma- 
tion progresses by 9 d after treatment to an extensive mono- 
cyte/CD3 +  cell population.  It  is  at  this  time that  serum 
cytokine levels are significantly increased compared with LPS 
only- or cytokine only-treated mice, and when cytokine- 
secreting cells can be detected within the heart tissue.  Addi- 
tionally, we find that the early, acute phase of myocarditis 
experienced  by mice infected only with CB3 is not associated 
with detectable serum concentrations of either IL-1 or TNF, 
nor is there immunohistological evidence of cytokine secre- 
tion in the few inflammatory cells present in the heart tissue 
of these mice before resolution of the diseases. 
Previous studies (22) in our laboratory have demonstrated 
that immunization of mice with mouse cardiac myosin results 
in chronic, autoimmune myocarditis, similar to that observed 
following acute CB3 infection. This disease is also  geneti- 
cally restricted, i.e., B10.A mice are resistant to the myosin- Figure 5.  H&E section  of  heart tissue obtained 
from B10.A mice cotreated  either with HE and 
IL-1 (not shown), or HE and TNF (A) demon- 
strated mononuclear  cell inflammation, whereas 
B10.A mice  treated  only  with FIE (B) experienced 
no inflammation ￿ 
induced autoimmune myocarditis. We found that immunizing 
B10.A mice with syngeneic heart extract, containing cardiac 
myosin in  addition to other cardiac proteins but  no CB3 
virus,  together with  IL-1 or TNF resulted in myocarditis 
in all animals (n  =  10 for both HE/IL-1 and HE/TNF), as 
seen in Fig.  5 A. Treatment of B10.A mice with syngeneic 
heart extract without IL-1 or TNF (n  =  5) produced no dis- 
ease  as  seen  in Fig.  5 B.  These observations and evidence 
presented in this report suggest that cytokine-mediated modu- 
lation  of the  immune  response leads  to  the  induction  of 
chronic, autoimmune myocarditis. 
It is possible that the extent of cytokine production during 
an organ-specific infectious process determines whether an 
autoimmune response will be directed towards that organ. 
B10.A mice may be resistant to the development of autoim- 
mune myocarditis because the cytokine levels obtained during 
1128  CB3-induced  Myocarditis  in Resistant B10.A Mice an immune response are properly balanced to ensure a con- 
trolled response to infected tissue. Manipulation of the cytokine 
levels upsets this balance, and may permit an uncontrolled 
immune response, or an inhibition of tolerance, to occur to- 
wards heart cell constituents, as observed in our whole heart 
extract experiments. If cytokines are found to play a significant 
role in the pathogenesis of this postinfectious autoimmune 
disease, then there would be potential therapeutic strategies 
for treating these diseases by reducing cytokine levels. 
This work was supported in part by the National  Institutes  of Health  grant  Hb33878. 
Address correspondence to Dr. Noel R.  Rose, The Johns Hopkins  University School of Hygiene and 
Public Health, Department of Immunology and Infectious Diseases, 615 N. Wolfe Street, Baltimore, MD 
21205. 
Received for publication 30 September 1991 and in revised  form  16 December 1991. 
References 
1.  Rose, N.R., A. Herskowitz,  D.A.  Neumann,  and N. Neu. 
1988. Autoimmune myocarditis: a paradigm of post-infection 
autoimmune  disease. Immunol. Today. 9:117. 
2.  Lane,  J.R., D.A. Neumann, A. Lafond-Walker,  A. Herskowitz, 
and N.R.  Rose. 1991. LPS promotes CB3-induced myocar- 
ditis in resistant B10.A mice. Cell. Immunol. 136:219. 
3.  Vogel, S.N.,  and M.M.  Hogan.  1990. Role of cytokines in 
endotoxin-mediated  host responses. In Immunophysiology:  The 
Role of Cells and Cytokines in Immunity and Inflammation. 
J.J. Oppenheim and E.M. Shevach, editors. Oxford Univer- 
sity Press, New York, 238-251. 
4.  Dinarello, C.A.  1984. Interleukin-1. Rev. Infect. l~'s. 6:51. 
5.  Beutler, B., and A. Cerami. 1987. Cachectin: more than a tumor 
necrosis factor. N. Engl. J. Med. 316:379. 
6.  Herskowitz, A., L.J. Wolfgram, N.R. Rose, and K.W. Beisel. 
1987. Coxsackie  virus B3 mufine myocarditis:  a pathogenic spec- 
trum of  myocarditis  in genetically  defined  inbred strains.J. Am. 
Coll. Cardiol. 9:1311. 
7.  Gudvangen, R.J., P.S. Duffey, R.E. Paque, and C.J. Gauntt. 
1983. Levamisole  exacerbates  Coxsackie virus B3-induced mu- 
fine myocarditis. Infect. lmmun. 41:1157. 
8.  Kimball, E.S., M.C. Clark, C.R. Schneider, and F.J. Persico. 
1991. Enhancement of in vitro lipopolysaccharide-stimulated 
interleukin-1  production by levamisole. Clin. Immunol. Im- 
munopatkol. 58:385. 
9.  Durum, S.K., J.J. Oppenheim, and R. Neta. 1990. Immuno- 
physiologic role of interleukin 1. In Immunophysiology: The 
Role of Cells and Cytokines in Immunity and Inflammation. 
J.J.  Oppenheim  and E.M. Shevach, editors. Oxford Univer- 
sity Press, New York, 210-225. 
10.  Kroemer, G., and A.C. Martinez. 1991. Cytokines and autoim- 
mune disease. Clin. Immunol. Immunopatkol. 61:275. 
11.  Merrill, J.E., S.R. Strom, G.W. EUison, and L.W. Meyers. 1989. 
In vitro study of mediators of inflammation in multiple scle- 
rosis. J. Clin. Immunol. 9:84. 
12.  Hofman, F.M., D.R. Hinton, K. Johnson,  and J.E.  Merrill. 
1989. Tumor necrosis  factor identified  in multiple sclerosis  brain. 
J. Exp. Med. 170:607. 
13.  Pabst, M.J., and R.B. Johnston. Bacterial lipopolysaccharide: 
a mediator of  inflammation. 1989. In Handbook of  Inflamma- 
tion, volume 6: mediators of the inflammatory process. P.M. 
Henson and R.C. Murphy, editors. Elsevier  Science  Publishing 
Co.,  Inc., New York, 361-393. 
14.  Antoni, G., R. Presentini, F. Perin, A. Tagliabue, P. Ghiara, 
S. Censini, G. Volpini, L. Villa, and D. Boraschi. 1986. A short 
synthetic peptide fragment of human interleukin  1 with im- 
munostimulatory  but not inflammatory activity. J. Immunol. 
137:3201. 
15.  Nencioni, L., L. Villa, A. Tagliabue, G. Antoni,  R. Presen- 
tini, F. Perin, S. Silvestri, and D. Borashi. 1987. In vivo im- 
munostimulating  activity of the 163-171 peptide of human 
Ibl. J. Immunol. 139:800. 
16.  Beutler, B., D. Greenwald, J.D. Hulmes, M. Chang, Y.-C.E. 
Pan, J. Mathison, R. Ulevitch, and A. Cerami. 1985. Identity 
of tumor necrosis factor and the macrophage-secreted factor 
cachectin. Nature (Lond.). 316:552. 
17.  Beutler, B., and A. Cerami. 1986. Cachectin and tumor necrosis 
factor as two sides of the same biological coin. Nature (Lond.). 
320:584. 
18.  Horn, J.T., A.M.  Bendele, and D.G. Carlson.  1988. In vivo 
administration  with  II.,1 accelerates the  development  of 
coUagen-induced arthritis  in mice. J. Immunol. 141:834. 
19.  Wilson,  C.A., C. Jacobs, P. Baker, D.G. Baskin, S. Dower, 
A. Lernmark, B. Toivola, S. Vertrees, and D. Wilson.  1990. 
Ibl modulation of spontaneous autoimmune diabetes and thy- 
roiditis in the BB rat. J. Immunol. 144:3784. 
20.  Beutler,  B.,  and  C.  Cerami.  1988. Tumor  necrosis factor, 
cachexia, shock, and inflammation: a common mediator. Annu. 
Rev. Biockem. 57:505. 
21.  PhiUip, R., and L.B. Epstein. 1986. Tumor necrosis factor as 
immunomodulator and mediator of  monocyte cytotoxicity in- 
duced by itself, gamma-interferon and interleukin-1. Nature 
(Lond.), 323:86. 
22.  Neu, N., N.R. Rose, K.W. Beisel, A. Herskowitz, G. Gurri- 
Glass, and S.W. Craig. 1987. Cardiac myosin induces myocar- 
ditis in genetically predisposed mice. J. Immunol. 139:3630. 
1129  Lane et al. 